-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BTIG Research Lowers Graphite Bio (NASDAQ:GRPH) to Neutral
BTIG Research Lowers Graphite Bio (NASDAQ:GRPH) to Neutral
BTIG Research downgraded shares of Graphite Bio (NASDAQ:GRPH – Get Rating) from a buy rating to a neutral rating in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports.
GRPH has been the topic of several other reports. SVB Leerink lowered shares of Graphite Bio from an outperform rating to a market perform rating and decreased their price objective for the stock from $11.00 to $2.00 in a research report on Friday, January 6th. Bank of America lowered shares of Graphite Bio from a buy rating to a neutral rating and decreased their price objective for the stock from $7.00 to $3.00 in a research report on Wednesday, January 18th. BMO Capital Markets lowered shares of Graphite Bio from an outperform rating to a market perform rating and decreased their price objective for the stock from $14.00 to $7.00 in a research report on Friday, January 6th. Finally, Royal Bank of Canada decreased their price objective on shares of Graphite Bio from $11.00 to $4.00 and set a sector perform rating on the stock in a research report on Friday, January 6th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Graphite Bio presently has an average rating of Hold and a consensus target price of $7.43.
Get Graphite Bio alerts:Graphite Bio Stock Performance
Shares of NASDAQ GRPH opened at $1.94 on Tuesday. The firm has a market capitalization of $112.81 million, a P/E ratio of -1.10 and a beta of 0.39. Graphite Bio has a one year low of $1.59 and a one year high of $11.30. The company's fifty day moving average is $2.82 and its two-hundred day moving average is $3.21.
Graphite Bio (NASDAQ:GRPH – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. On average, sell-side analysts forecast that Graphite Bio will post -1.88 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Prelude Capital Management LLC acquired a new position in Graphite Bio in the 2nd quarter valued at about $67,000. Walleye Capital LLC acquired a new position in Graphite Bio in the 1st quarter valued at about $57,000. Jane Street Group LLC acquired a new position in Graphite Bio in the 3rd quarter valued at about $37,000. Dimensional Fund Advisors LP acquired a new position in shares of Graphite Bio during the 3rd quarter valued at about $34,000. Finally, Prosight Management LP acquired a new position in shares of Graphite Bio during the 3rd quarter valued at about $1,130,000. Institutional investors and hedge funds own 52.51% of the company's stock.
About Graphite Bio
(Get Rating)
Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
Featured Stories
- Get a free copy of the StockNews.com research report on Graphite Bio (GRPH)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
BTIG Research下调了对石墨生物(纳斯达克:grph-Get Rating)据MarketBeat Ratings报道,在周二上午发布给投资者的一份研究报告中,评级从买入评级转为中性评级。
GRPH一直是其他几份报告的主题。在1月6日星期五的一份研究报告中,SVB Leerink将Graphite Bio的股票评级从跑赢大盘下调至市场表现评级,并将其股票目标价从11.00美元下调至2.00美元。在1月18日星期三的一份研究报告中,美国银行将Graphite Bio的股票评级从买入下调至中性评级,并将该股的目标价从7.00美元下调至3.00美元。BMO Capital Markets在1月6日星期五的一份研究报告中将Graphite Bio的股票评级从跑赢大盘下调至市场表现评级,并将该股的目标价从14.00美元下调至7.00美元。最后,加拿大皇家银行在1月6日星期五的一份研究报告中将石墨生物的股票目标价从11.00美元下调至4.00美元,并对该股设定了行业表现评级。六位分析师对该股的评级为持有,一位分析师对该股的评级为买入。根据MarketBeat.com的数据,Graphite Bio目前的平均评级为持有,共识目标价为7.43美元。
到达石墨生物警报:石墨生物质股表现
周二,纳斯达克的股价开盘报1.94美元。该公司的市值为1.1281亿美元,市盈率为-1.10,贝塔系数为0.39。石墨生物的一年低点为1.59美元,一年高位为11.30美元。该公司的50日移动均线切入位在2.82美元,200日移动均线切入位在3.21美元。
石墨生物(纳斯达克:GRPH-GET评级)最近一次发布财报是在11月9日(星期三)。该公司公布本季度每股收益(0.45美元),比普遍预期的(0.49美元)高出0.04美元。卖方分析师平均预测,Graphite Bio本财年每股收益将达到1.88美元。机构资金流入和流出
机构投资者最近增持或减持了该公司的股份。Prelude Capital Management LLC在第二季度收购了Graphite Bio的一个新头寸,价值约6.7万美元。Walleye Capital LLC在第一季度收购了Graphite Bio的一个新头寸,价值约57,000美元。简街集团在第三季度收购了Graphite Bio的一个新头寸,价值约3.7万美元。Dimension Fund Advisors LP在第三季度收购了Graphite Bio股票的新头寸,价值约3.4万美元。最后,Prosight Management LP在第三季度收购了Graphite Bio的新股票,价值约为113万美元。机构投资者和对冲基金持有该公司52.51%的股票。
关于石墨生物
(获取评级)
石墨生物公司是一家临床阶段的基因编辑公司,在美国致力于开发严重和危及生命的疾病的治疗方法。它提供了GPH101,这是一种经过基因编辑的自体造血干细胞候选产品,可以直接纠正导致镰状细胞疾病的突变并恢复正常的成人血红蛋白表达;GPH201,用于治疗X连锁严重联合免疫缺陷综合征;以及GPH301,用于治疗高谢病,这是一种导致葡萄糖脑苷酶缺乏的遗传性疾病。
专题报道
- 免费获取StockNews.com关于石墨生物的研究报告(GRPH)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
接受《石墨生物日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Graphite Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧